Gonadotropin-suppressive therapy in girls with early and fast puberty affects the pace of puberty but not total pubertal growth or final height

Journal of Clinical Endocrinology and Metabolism

Volumn 87, Issue 5, 2002, Pages 2090-2094

  Lazar, L ^a,b   Kauli, R ^a   Pertzelan, A ^a   Phillip, M ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GONADORELIN DERIVATIVE; LUTEINIZING HORMONE; TRIPTORELIN;

ARTICLE; BODY HEIGHT; BODY WEIGHT; BONE MATURATION; FEMALE; GROWTH RATE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PUBERTY; SCHOOL CHILD; TREATMENT OUTCOME;

EID: 0036093278     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.87.5.8481     Document Type: Article

References (35)

1. Puberty: Ontogeny, neuroendocrinology, physiology, and disorders
2. Disorders of puberty
3. Physical changes of puberty
4. Idiopathic precocious puberty in girls: Long-term effects on adolescent behavior
5. Clinical review 60: Effects of gonadotrophin-releasing hormone analogue therapy on adult stature in precocious puberty
6. Randomized trial of LHRH analogue treatment on final height in girls with onset of puberty aged 7.5-8.5 years
7. Lack of effect of GnRH agonist on final height in girls with advanced puberty: A randomized long term pilot study
8. Long-term effect of gonadotropin-releasing hormone agonist therapy on final and near-final height in 26 children with true precocious puberty treated at a median age of less than 5 years
9. Final height after long-term treatment with triptorelin slow release for central precocious puberty: Importance of statural growth after interruption of treatment
10. Final height in central precocious puberty after long-term treatment with a slow-release GnRH agonist
11. The effect of luteinizing hormone-releasing hormone analogue for central precocious puberty on growth hormone (GH) and GH-binding protein
12. Effect of combined treatment with gonadotropin releasing hormone analogue and growth hormone in patients with central precocious puberty who had subnormal growth velocity and impaired height prognosis
13. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: Long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty
14. Bone mineral density and body composition before and during treatment with gonadotropin-releasing hormone agonist in children with central precocious puberty and early puberty
15. Final height (FHt) of girls with early and fast puberty - Untreated versus treated with GnRH analogue (GnRHA)
16. Variations in the pattern of pubertal changes in girls
17. Standards for ovarian volumes in childhood and puberty
18. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty
19. Percentiles for body mass index in US children 5 to 17 years of age
20. Tables for predicting adult height from skeletal age
21. Final height of girls with central precocious puberty untreated versus treated with cyproterone acetate or GnRH analogue
22. Standards for children's height at age 2-9 years allowing for height of parents
23. Pubertal development, growth and final height in girls with sexual precocity after therapy with GnRH-analogue D-TRP-6-LHRH
24. Effects of long term gonadotropin-releasing hormone analogue treatment on growth, growth hormone (GH) secretion, GH receptors and GH binding proteins in the rat
25. Growth hormone secretion is normal in girls with precocious puberty during suppressive therapy with LH-RH analogue (T-TRP-6-LH-RH)
26. Adult height comparison between boys and girls with precocious puberty after long-term gonadotropin-releasing hormone analogue therapy
27. Long-term GnRH agonist treatment does not postpone central development of the GnRH pulse generator in girls with idiopathic precocious puberty
28. Treatment of central precocious puberty. Lessons from a 15-year prospective trial
29. Age dependent responsiveness of rabbit and human cartilage cells to sex steroids in vitro
30. Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty
31. Rapid maturation in adolescence results in greater obesity in adulthood: The Amsterdam Growth and Health Study
32. Secondary sexual characteristics and menses in young girls seen in office practice: A study from the Pediatric Research in Office Settings Network
33. Reexamination of the age limit for defining when puberty is precocious in girls in the United States: Implications for evaluation and treatment